Harrow Launches BYOOVIZ Biosimilar
Harrow announced the commercial launch of BYOOVIZ, an FDA-approved biosimilar referencing LUCENTISi and developed by Samsung Bioepis. The launch follows Harrow's exclusive U.S. commercialization agreement with Samsung Bioepis, one of the world's leading biosimilar developers and manufacturers. Through this partnership, Harrow obtained exclusive U.S. rights to commercialize BYOOVIZ and OPUVIZ, an FDA-approved biosimilar referencing EYLEAii, further strengthening the Company's position in the rapidly growing retinal biologics market.
